Establishment and characterization of novel high mucus-producing lung tumoroids derived from a patient with pulmonary solid adenocarcinoma
Human Cell · 2024
DOI: 10.1007/s13577-024-01060-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Cell, 2024. Verfasst von Miki Iwai und 9 weiteren Autor:innen. Beteiligte Einrichtung: General Medical Center Research Unit, Kawasaki Medical School, Okayama, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Mucus, Adenocarcinoma, Adenocarcinoma of Lung. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan.
Abstract (Originalsprache)
Among mucus-producing lung cancers, invasive mucinous adenocarcinoma of the lung is a rare and unique subtype of pulmonary adenocarcinoma. Notably, mucus production may also be observed in the five subtypes of adenocarcinoma grouped under the higher-level diagnosis of Invasive Non-mucinous Adenocarcinomas (NMA). Overlapping pathologic features in mucus-producing tumors can cause diagnostic confusion with significant clinical consequences. In this study, we established lung tumoroids, PDT-LUAD#99, from a patient with NMA and mucus production. The tumoroids were derived from the malignant pleural effusion of a patient with lung cancer and have been successfully developed for long-term culture (> 11 months). Karyotyping by fluorescence in situ hybridization using an alpha-satellite probe showed that tumoroids harbored aneuploid karyotypes. Subcutaneous inoculation of PDT-LUAD#99 lung tumoroids into immunodeficient mice resulted in tumor formation, suggesting that the tumoroids were derived from cancer. Xenografts from PDT-LUAD#99 lung tumoroids reproduced the solid adenocarcinoma with mucin production that was observed in the patient's metastatic lymph nodes. Immunoblot analysis showed MUC5AC secretion into the culture supernatant of PDT-LUAD#99 lung tumoroids, which in contradistinction was barely detected in the culture supernatants of NCI-A549 and NCI-H2122 pulmonary adenocarcinoma cells known for their mucin-producing abilities. Here, we established a novel high-mucus-producing lung tumoroids from a solid adenocarcinoma. This preclinical model may be useful for elucidating the pathogenesis of mucus-producing lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Medical Center Research Unit, Kawasaki Medical School, Okayama, Japan.
- Department of General Surgery, Kawasaki Medical School, Okayama, Japan.
- Okayama Medical Laboratories Co., Ltd., Kurashiki, Japan.
- Kawasaki Medical School General Medical Center, Okayama, Japan.
- Department of Medical Care Work, Kawasaki College of Health Professions, Okayama, Japan.
- Kawasaki Geriatric Medical Center, Okayama, Japan.
Förderung
- The Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan
Zitieren
APA
Iwai, M., Yokota, E., Ishida, Y., Yukawa, T., Naomoto, Y., Monobe, Y., Haisa, M., Takigawa, N., Fukazawa, T., & Yamatsuji, T. (2024). Establishment and characterization of novel high mucus-producing lung tumoroids derived from a patient with pulmonary solid adenocarcinoma. Human Cell. https://doi.org/10.1007/s13577-024-01060-3
Vancouver
Iwai M, Yokota E, Ishida Y, Yukawa T, Naomoto Y, Monobe Y, et al. Establishment and characterization of novel high mucus-producing lung tumoroids derived from a patient with pulmonary solid adenocarcinoma. Human Cell. 2024. doi:10.1007/s13577-024-01060-3
BibTeX
@article{Iwai2024,
author = {Iwai, Miki and Yokota, Etsuko and Ishida, Yuta and Yukawa, Takuro and Naomoto, Yoshio and Monobe, Yasumasa and Haisa, Minoru and Takigawa, Nagio and Fukazawa, Takuya and Yamatsuji, Tomoki},
title = {Establishment and characterization of novel high mucus-producing lung tumoroids derived from a patient with pulmonary solid adenocarcinoma},
journal = {Human Cell},
year = {2024},
doi = {10.1007/s13577-024-01060-3}
}
EUVIMED